Anti-Human Frizzled receptor Recombinant Antibody (Vantictumab) (CAT#: TAB-880)

Figure 1 WNT antagonists synergize with taxanes.

Vantictumab (VAN) has greater tumor growth inhibition when combined with nab-paclitaxel than gemcitabine. OMP-PN13 was treated with vantictumab (25 mg/kg) every 2 weeks and with gemcitabine (gem; 25 mg/kg) or nab-paclitaxel (nab-pac; 30 mg/kg) every week (n = 7 to 9 per group).

Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., ... & O’Young, G. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science advances, 3(6), e1700090.

Figure 2 Vantictumab (VAN) inhibits the tumor growth significantly.

OMP-PN25 was treated with vantictumab (25 mg/kg) every 2 weeks and with gemcitabine (20 mg/kg) or nab- paclitaxel (15 mg/kg) every week (n = 5 to 10 per group). mAb, monoclonal antibody.

Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., ... & O’Young, G. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science advances, 3(6), e1700090.

Figure 3 Administration of vantictumab or ipafricept 2 days before paclitaxel is essential for blocking tumor growth.

UM-PE13 treated with vantictumab (25 mg/kg) on day 1 or 4 with paclitaxel (pac; 20 mg/kg) given on day 1 or 4 in 3-week cycles (n = 6 to 8 per group).

Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., ... & O’Young, G. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science advances, 3(6), e1700090.

Figure 4 Sequential dosing of vantictumab and paclitaxel potentiates mitotic cell death in breast cancer.

OMP-B90 and UM-PE13 breast tumors respond to sequential vantictumab followed by paclitaxel. For OMP-B90, vantictumab (25 mg/kg) was administered on day 1 in 2-week cycles, for a total of six cycles. Paclitaxel (10 mg/kg) was given on day 1 or 3 in weekly cycles. For UM-PE13, vantictumab (25 mg/kg) was given on day 1 or 3, every other week, whereas paclitaxel (10 mg/kg) was given on day 3 every week.

Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., ... & O’Young, G. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science advances, 3(6), e1700090.

Figure 5 Sequential dosing of vantictumab and paclitaxel potentiates mitotic cell death in breast cancer.

Vantictumab promotes P21 induction and blockade of cyclin expression in OMP-B90.

Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., ... & O’Young, G. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science advances, 3(6), e1700090.

Figure 1 Anti-Human Frizzled receptor Antibody (TAB-880) in SDS-PAGE

Lane 1: Non-reduced mAb
Lane 2: Reduced mAb

Figure 2 Anti-Human Frizzled receptor Antibody (TAB-880) in HPLC

SEC-HPLC analysis of TAB-880 shows that the purity is more than 95%.

Figure 3 Anti-Human Frizzled receptor Antibody (TAB-880) in ELISA

ELISA analysis of TAB-880 was performed by coating with Recombinant Human Frizzled-2/FZD2 Protein.

The secondary antibody: HRP Mouse Anti-His tag